Outlook for the Second Half

vs Plan revised in August

Food Segment

 • Decrease sales and operating income targets to reflect operating performance in H1

 • Restate operating income target to JPY 49.1 billion (secure JPY 49.0 billion, initial target set in April)

Pharmaceutical Segment

 • Increase sales and operating income targets

 • Consolidated KM Biologics

Meiji Group (consolidated)

 • Increase sales target and decrease operating income target